Our top pick for
BeiGene, Ltd is a biotechnology business based in the US. BeiGene shares (BGNE) are listed on the NASDAQ and all prices are listed in US Dollars. BeiGene employs 5,300 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$136.48 - $388.97|
|50-day moving average||$323.12|
|200-day moving average||$304.90|
|Wall St. target price||$357.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-11.29|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$308.9 million|
|Gross profit TTM||$-1,056,660,000|
|Return on assets TTM||-28.73%|
|Return on equity TTM||-66.03%|
|Market capitalisation||$31.1 billion|
TTM: trailing 12 months
There are currently 2.6 million BeiGene shares held short by investors – that's known as BeiGene's "short interest". This figure is 1.1% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting BeiGene shares can be evaluated.
BeiGene's "short interest ratio" (SIR) is the quantity of BeiGene shares currently shorted divided by the average quantity of BeiGene shares traded daily (recently around 245664.36018957). BeiGene's SIR currently stands at 10.55. In other words for every 100,000 BeiGene shares traded daily on the market, roughly 10550 shares are currently held short.
However BeiGene's short interest can also be evaluated against the total number of BeiGene shares, or, against the total number of tradable BeiGene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeiGene's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BeiGene shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BeiGene shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BeiGene.
Find out more about how you can short BeiGene stock.
We're not expecting BeiGene to pay a dividend over the next 12 months.
Over the last 12 months, BeiGene's shares have ranged in value from as little as $136.48 up to $388.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeiGene's is 0.9162. This would suggest that BeiGene's shares are less volatile than average (for this exchange).
BeiGene, Ltd. , a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.